NCT07338786

A Phase I Clinical Trial to Evaluate the Safety of Different Immunization Schedules of a Lyophilized Human Rabies Vaccine (Human Diploid Cell)

A Single-Center, Open-Label, Single-Arm, Phase I Clinical Trial to Evaluate the Safety of a Lyophilized Human Rabies Vaccine (Human Diploid Cell) Administered in Different Immunization Schedules.

• Status: Enrolling By Invitation
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 80 (estimated)
• Sponsor: Changchun BCHT Biotechnology Co. · Industry
• Sex: All
• Age: 10 Years – 60 Years
• Healthy volunteers: Accepted

Summary

This clinical trial employed a single-center, open-label, single-arm design. A total of 80 participants aged 10 to 60 years were enrolled and divided into two age groups: 40 in the 18-60 years cohort and 40 in the 10-17 years cohort. All participants received the lyophilized human rabies vaccine (human diploid cell)

Conditions

• RabiesPrevention

Interventions

Type	Name	Description
DRUG	Lyophilized Human Rabies Vaccine (Human Diploid Cell)	Each human dose is 0.5 ml.

Timeline

• Start date: 2025-09-13
• Primary completion: 2026-01-04
• Completion: 2026-05-01
• First posted: 2026-01-14
• Last updated: 2026-01-14

Locations

1 site across 1 country: China